All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
During the 4th European CAR T-Cell Meeting, the Lymphoma Hub was pleased to speak to Arnon Nagler, Sheba Medical Center, Tel Aviv, IL. We asked, how do CAR T-cell recipients respond to COVID-19 vaccination?
How do CAR T-cell recipients respond to COVID-19 vaccination?
In this video, Nagler discusses chimeric antigen receptor (CAR) T-cell therapy (CAR-T). He also highlights the challenges that COVID-19 has caused to CAR-T and the implications for patients with; Non-Hodgkin lymphoma, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
When is CAR-T a good option for patients with follicular and marginal zone lymphomas?
During the 4th European CAR T-cell Meeting, the Lymphoma Hub was pleased to speak with Gilles Salles, Memorial Sloane Kettering Cancer Center, New York, US. We...
NCCN COVID-19 vaccination recommendations for patients with hematologic malignancies
Patients with cancer are at high risk of COVID-19-associated complications and, accordingly, the preliminary recommendations issued by the National Comprehensive...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox